^
    Apply
    FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (NCT03926936)
    Phase 2
    Frederic Amant
    Completed
    Last update posted :
    05/27/2024
    Initiation :
    03/13/2019
    Primary completion :
    04/01/2022
    Completion :
    12/27/2022
    ER
    |
    ER positive
    |
    fulvestrant
    Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (NCT02428192)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/02/2024
    Initiation :
    04/22/2015
    Primary completion :
    09/20/2018
    Completion :
    03/05/2025
    PD-1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)
    Letrozole in Uterine Leiomyosarcoma (NCT05649956)
    Phase 2
    GOG Foundation
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    03/01/2024
    Primary completion :
    06/30/2028
    Completion :
    06/30/2029
    ER
    |
    letrozole
    Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (NCT00856050)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    04/18/2017
    Initiation :
    02/01/2009
    Primary completion :
    01/01/2013
    Completion :
    03/01/2014
    ER • PGR
    |
    letrozole